Panacea Biotec Announces 42nd AGM on Sept 29, 2026, with E-voting Facility
Panacea Biotec's 42nd AGM is scheduled for September 29, 2026, conducted via VC/OAVM. The company will present its FY26 audited financial statements. Key agenda items include re-appointment of two directors and appointment of an independent director. Remote e-voting is available from Sept 26-28, 2026.
This is a standard procedural announcement regarding an upcoming AGM and does not involve any immediate material changes to the company's operations, financials, or strategic direction.
The announcement is a routine corporate event (AGM notification) with no new financial performance data or significant business updates that would sway sentiment positively or negatively.
Panacea Biotec Limited has announced that its 42nd Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 11:30 A.M. IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM). This is in continuation of their earlier intimation on August 13, 2026.
The company will be sending the Annual Report for the financial year 2025-26 and the Notice of the 42nd AGM to its members through electronic mode. Shareholders will have the opportunity to cast their votes electronically through a remote e-voting facility.
The cut-off date for determining eligibility for remote e-voting is Tuesday, September 22, 2026. The remote e-voting period will commence on Saturday, September 26, 2026, from 09:00 a.m. IST and conclude on Monday, September 28, 2026, at 05:00 p.m. IST. The e-voting facility will also be available during the AGM itself for those attending virtually.
The AGM agenda includes the consideration and adoption of the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. Additionally, the meeting will address the re-appointment of directors Mr. Ankesh Jain and Mr. Harshet Jain, who are retiring by rotation. The appointment of Mr. Rajinder Singh Manku as an independent director for a period of five consecutive years from July 01, 2026, will also be considered. Furthermore, the remuneration of the Cost Auditors for the financial year 2026-27 will be ratified.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.